BEAM
Price
$25.79
Change
+$0.09 (+0.35%)
Updated
Mar 11, 02:49 PM (EDT)
Capitalization
2.38B
63 days until earnings call
ERAS
Price
$1.46
Change
+$0.03 (+2.10%)
Updated
Mar 11, 02:05 PM (EDT)
Capitalization
432.57M
9 days until earnings call
Ad is loading...

BEAM vs ERAS

Header iconBEAM vs ERAS Comparison
Open Charts BEAM vs ERASBanner chart's image
Beam Therapeutics
Price$25.79
Change+$0.09 (+0.35%)
Volume$843
Capitalization2.38B
Erasca
Price$1.46
Change+$0.03 (+2.10%)
Volume$100
Capitalization432.57M
BEAM vs ERAS Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. ERAS commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and ERAS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (BEAM: $25.69 vs. ERAS: $1.42)
Brand notoriety: BEAM and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 582% vs. ERAS: 117%
Market capitalization -- BEAM: $2.38B vs. ERAS: $432.57M
BEAM [@Biotechnology] is valued at $2.38B. ERAS’s [@Biotechnology] market capitalization is $432.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both BEAM and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 7 bearish.
  • ERAS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +2.35% price change this week, while ERAS (@Biotechnology) price change was +10.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.77%. For the same industry, the average monthly price growth was -9.35%, and the average quarterly price growth was -8.79%.

Reported Earning Dates

BEAM is expected to report earnings on May 13, 2025.

ERAS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-0.77% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.38B) has a higher market cap than ERAS($433M). BEAM YTD gains are higher at: 3.589 vs. ERAS (-43.426). ERAS has higher annual earnings (EBITDA): -151.33M vs. BEAM (-160.83M). BEAM has more cash in the bank: 926M vs. ERAS (319M). ERAS has less debt than BEAM: ERAS (52.9M) vs BEAM (162M). BEAM has higher revenues than ERAS: BEAM (350M) vs ERAS (0).
BEAMERASBEAM / ERAS
Capitalization2.38B433M550%
EBITDA-160.83M-151.33M106%
Gain YTD3.589-43.426-8%
P/E RatioN/AN/A-
Revenue350M0-
Total Cash926M319M290%
Total Debt162M52.9M306%
TECHNICAL ANALYSIS
Technical Analysis
BEAMERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 13 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DREGX37.62N/A
N/A
Driehaus Emerging Markets Growth Inv
GEGAX13.85N/A
N/A
abrdn Emerging Markets A
FVIFX33.64N/A
N/A
Fidelity Advisor Value I
FBBAX26.05N/A
N/A
First Foundation Total Return A
SMCFX65.25-1.87
-2.79%
American Funds SMALLCAP World F2

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with KYMR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-7.19%
KYMR - ERAS
48%
Loosely correlated
+0.40%
RYTM - ERAS
48%
Loosely correlated
-4.23%
XNCR - ERAS
47%
Loosely correlated
-1.59%
RVMD - ERAS
45%
Loosely correlated
-5.99%
RCKT - ERAS
45%
Loosely correlated
-2.05%
More